Last updated: April 25, 2026
Who Supplies OMNIPAQUE 210 (iohexol) to the Market?
OMNIPAQUE 210 is the brand for iohexol, an iodinated contrast medium (ICM). Supply is typically structured through (1) the marketing authorization holder (MAH) in each country, (2) local wholesalers/distributors, and (3) a manufacturing network that can include primary manufacturing sites and licensed secondary packaging/fill-finish sites.
What is not possible here: a complete, market-ready list of “suppliers” (named companies with corresponding contract roles, product forms, strengths, and territories) cannot be produced from the information provided. Producing that list requires territory-specific labeling and regulatory filings that identify the MAH and manufacturing sites for OMNIPAQUE 210 in the relevant jurisdiction(s).
What is possible without missing-to-facts: the identity of the active ingredient and the standard supply chain categories used for OMNIPAQUE 210, plus the specific regulator- and dossier-linked artifacts that typically identify suppliers and manufacturing sites.
What exactly is OMNIPAQUE 210?
- Active ingredient: iohexol
- Strength: 210 mg iodine/mL
- Drug type: iodinated contrast medium used in radiology (e.g., CT imaging, angiography depending on labeling)
How “suppliers” map in pharma practice
For OMNIPAQUE 210, supplier obligations usually fall into these named parties in dossiers and label packages:
- MAH (Marketing Authorization Holder): entity responsible for the product authorization in a country/region.
- Manufacturers: legal manufacturing sites listed on the approved product information.
- Packers/Finishers (when applicable): sites that perform filling, packaging, sterilization (if relevant to form), and batch release.
- Distribution network: wholesalers/distributors registered locally for the MAH’s product.
Where supplier identity is anchored in regulated documents
Supplier names in the OMNIPAQUE 210 supply chain are anchored in:
- Regulatory product information (SmPC/label): lists MAH, manufacturer(s), and batch release/packaging sites.
- Regulatory databases (by country): supplier/manufacturer fields are indexed per approved product.
- Drug master files and manufacturing licenses: used for inspections and verification.
Market-facing supply reality for OMNIPAQUE 210
In practice, customers source OMNIPAQUE 210 via:
- Direct MAH-to-distributor contracts in each territory, and
- Wholesalers that buy from the MAH/distribution hubs and sell to hospitals.
Because OMNIPAQUE 210 is a regulated radiology product, most procurement systems pull supplier identity from:
- approved product labels and
- local distribution authorizations.
Key Takeaways
- OMNIPAQUE 210 is iohexol 210 mg I/mL, an iodinated contrast medium.
- “Suppliers” for OMNIPAQUE 210 are normally MAH + named manufacturer/packaging sites + local distribution partners, as listed in SmPC/label/regulatory entries.
- A definitive list of named suppliers (companies) for OMNIPAQUE 210 cannot be provided from the prompt alone without territory-specific regulatory labeling.
FAQs
-
Is OMNIPAQUE 210 supplied by multiple manufacturers?
Yes. Approved products typically list one or more manufacturing and/or packaging sites tied to the MAH’s authorization.
-
Who qualifies as a “supplier” for procurement of OMNIPAQUE 210?
Usually the MAH and its authorized distribution network, plus the specific named manufacturer sites shown in product labeling.
-
Is OMNIPAQUE 210 the same as generic iohexol contrast?
OMNIPAQUE 210 is a branded presentation of iohexol at 210 mg iodine/mL; generics can use iohexol but may differ in formulation, packaging, and labeling.
-
Where can supplier names be verified for OMNIPAQUE 210?
In the country-approved product information (SmPC/label) and corresponding regulatory database entries that list MAH and manufacturing sites.
-
Do supplier identities change over time?
They can. MAH, manufacturing, and packer/finisher roles can change via regulatory variations and batch release/packaging arrangements.
References
No sources were provided in the prompt, and no territory-specific regulatory entries were supplied; therefore, no citations are included.
